BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 17013093)

  • 1. Cyclin-dependent kinase 2 expression in human melanomas and benign melanocytic skin lesions.
    Kuźbicki L; Aładowicz E; Chwirot BW
    Melanoma Res; 2006 Oct; 16(5):435-44. PubMed ID: 17013093
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of cyclooxygenase-2 in benign naevi and during human cutaneous melanoma progression.
    Kuźbicki L; Sarnecka A; Chwirot BW
    Melanoma Res; 2006 Feb; 16(1):29-36. PubMed ID: 16432453
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Different expression of lysosome-associated membrane protein-1 in human melanomas and benign melanocytic lesions.
    Kuźbicki L; Gajo B; Chwirot BW
    Melanoma Res; 2006 Jun; 16(3):235-43. PubMed ID: 16718270
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclin D1 expression in melanocytic lesions of the skin.
    Ramirez JA; Guitart J; Rao MS; Diaz LK
    Ann Diagn Pathol; 2005 Aug; 9(4):185-8. PubMed ID: 16084449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase-2 (COX-2): first immunohistochemical marker distinguishing early cutaneous melanomas from benign melanocytic skin tumours.
    Chwirot BW; Kuźbicki Ł
    Melanoma Res; 2007 Jun; 17(3):139-45. PubMed ID: 17505259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
    Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
    Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
    Fullen DR; Zhu W; Thomas D; Su LD
    J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns of melastatin mRNA expression in melanocytic tumors.
    Deeds J; Cronin F; Duncan LM
    Hum Pathol; 2000 Nov; 31(11):1346-56. PubMed ID: 11112208
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value.
    Väisänen A; Tuominen H; Kallioinen M; Turpeenniemi-Hujanen T
    J Pathol; 1996 Nov; 180(3):283-9. PubMed ID: 8958806
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma.
    Prieto VG; Mourad-Zeidan AA; Melnikova V; Johnson MM; Lopez A; Diwan AH; Lazar AJ; Shen SS; Zhang PS; Reed JA; Gershenwald JE; Raz A; Bar-Eli M
    Clin Cancer Res; 2006 Nov; 12(22):6709-15. PubMed ID: 17121890
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Up-regulation of growth hormone receptor immunoreactivity in human melanoma.
    Lincoln DT; Sinowatz F; Kölle S; Takahashi H; Parsons P; Waters M
    Anticancer Res; 1999; 19(3A):1919-31. PubMed ID: 10470136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Value of dopachrome tautomerase detection in the assessment of melanocytic tumors.
    Filimon A; Zurac SA; Milac AL; Sima LE; Petrescu SM; Negroiu G
    Melanoma Res; 2014 Jun; 24(3):219-36. PubMed ID: 24709887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases.
    Boyd AS; Shakhtour B; Shyr Y
    J Am Acad Dermatol; 2008 May; 58(5):750-4. PubMed ID: 18249467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced p16 and increased cyclin D1 and pRb expression are correlated with progression in cutaneous melanocytic tumors.
    Karim RZ; Li W; Sanki A; Colman MH; Yang YH; Thompson JF; Scolyer RA
    Int J Surg Pathol; 2009 Oct; 17(5):361-7. PubMed ID: 19666944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrophage migration inhibitory factor protein and mRNA expression in cutaneous melanocytic tumours.
    Miracco C; De Nisi MC; Arcuri F; Cosci E; Pacenti L; Toscano M; Lalinga AV; Biagioli M; Rubegni P; Vatti R; Maellaro E; Del Bello B; Massi D; Luzi P; Tosi P
    Int J Oncol; 2006 Feb; 28(2):345-52. PubMed ID: 16391788
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi.
    Sand M; Gambichler T; Sand D; Altmeyer P; Stuecker M; Bechara FG
    Eur J Dermatol; 2011; 21(1):18-21. PubMed ID: 21262599
    [TBL] [Abstract][Full Text] [Related]  

  • 17. JARID1B expression in human melanoma and benign melanocytic skin lesions.
    Kuźbicki L; Lange D; Strączyńska-Niemiec A; Chwirot BW
    Melanoma Res; 2013 Feb; 23(1):8-12. PubMed ID: 23262439
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of fatty acid synthase (FASN) in oral nevi and melanoma.
    de Andrade BA; León JE; Carlos R; Delgado-Azañero W; Mosqueda-Taylor A; Graner E; de Almeida OP
    Oral Dis; 2011 Nov; 17(8):808-12. PubMed ID: 21819495
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of EphB6 expression in metastatic melanoma.
    Hafner C; Bataille F; Meyer S; Becker B; Roesch A; Landthaler M; Vogt T
    Int J Oncol; 2003 Dec; 23(6):1553-9. PubMed ID: 14612926
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P21 and Bax expression in cutaneous malignant melanomas: correlation with histologic prognostic parameters.
    Poyraz A; Akyürek N; Gönül II; Erdem O
    J Exp Clin Cancer Res; 2004 Dec; 23(4):625-31. PubMed ID: 15743033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.